Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares Issued
Ratios

Akebia Therapeutics (AKBA) Accumulated Depreciation & Amortization (2016 - 2022)

Historic Accumulated Depreciation & Amortization for Akebia Therapeutics (AKBA) over the last 7 years, with Q4 2022 value amounting to $1.7 million.

  • Akebia Therapeutics' Accumulated Depreciation & Amortization fell 1416.71% to $1.7 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.7 million, marking a year-over-year decrease of 1416.71%. This contributed to the annual value of $1.7 million for FY2022, which is 1416.71% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Accumulated Depreciation & Amortization of $1.7 million as of Q4 2022, which was down 1416.71% from $1.9 million recorded in Q4 2021.
  • Over the past 5 years, Akebia Therapeutics' Accumulated Depreciation & Amortization peaked at $5.2 million during Q3 2020, and registered a low of $899000.0 during Q4 2018.
  • Its 5-year average for Accumulated Depreciation & Amortization is $2.6 million, with a median of $2.2 million in 2019.
  • As far as peak fluctuations go, Akebia Therapeutics' Accumulated Depreciation & Amortization crashed by 1510.86% in 2018, and later surged by 14972.19% in 2019.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Accumulated Depreciation & Amortization stood at $899000.0 in 2018, then soared by 149.72% to $2.2 million in 2019, then dropped by 7.57% to $2.1 million in 2020, then dropped by 7.13% to $1.9 million in 2021, then fell by 14.17% to $1.7 million in 2022.
  • Its Accumulated Depreciation & Amortization stands at $1.7 million for Q4 2022, versus $1.9 million for Q4 2021 and $2.1 million for Q4 2020.